Armored CAR T cells safe, clinically active in advanced pediatric liver cancer

A novel armored chimeric antigen receptor T-cell therapy targeting the glypican-3 protein showed antitumor activity among children with advanced liver cancer, according to preliminary results of a phase 1 trial presented at the virtual American Society of Gene and Cell Therapy Annual Meeting.The armored glypican-3 (GPC3) CAR T-cell therapy also exhibited an acceptable safety profile.Glypican-3 is heavily expressed by multiple liver tumors but normally absent in healthy tissue, making it an attractive target for CAR T-cell therapy, according to David Steffin, MD, assistant professor at BaylorRead More

Share on facebook
Share on twitter
Share on linkedin